Regeneus logo

RGS - Regeneus Share Price

A$0.11 -0.0  -8.3%

Last Trade - 05/03/21

Sector
Healthcare
Size
Micro Cap
Market Cap £17.0m
Enterprise Value £14.4m
Revenue £4.85m
Position in Universe 1271st / 1857
Bullish
Bearish
Unlock RGS Revenue
Momentum
Relative Strength (%)
1m +2.13%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.06 1.88 10.1 0.61 0.000 1.66 2.79 4.19 -4.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, RegeneusLtd revenues increased from A$1K to A$7.1M. Net incometotaled A$4.4M vs. loss of A$1.2M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net Income reflectsResearch and development expenses decrease of 40% to A$510K(expense), Occupancy Expenses decrease of 80% to A$47K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RGS Revenue Unlock RGS Revenue

Net Income

RGS Net Income Unlock RGS Revenue

Normalised EPS

RGS Normalised EPS Unlock RGS Revenue

PE Ratio Range

RGS PE Ratio Range Unlock RGS Revenue

Dividend Yield Range

RGS Dividend Yield Range Unlock RGS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RGS EPS Forecasts Unlock RGS Revenue
Profile Summary

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated August 14, 2007
Public Since September 18, 2013
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 277,824,988
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RGS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RGS
Upcoming Events for RGS
Frequently Asked Questions for Regeneus
What is the Regeneus share price?

As of 05/03/21, shares in Regeneus are trading at A$0.11, giving the company a market capitalisation of £17.0m. This share price information is delayed by 15 minutes.

How has the Regeneus share price performed this year?

Shares in Regeneus are currently trading at A$0.11 and the price has moved by 32.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Regeneus price has moved by 23.55% over the past year.

What are the analyst and broker recommendations for Regeneus?

Of the analysts with advisory recommendations for Regeneus, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Regeneus is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Regeneus next release its financial results?

Regeneus is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Regeneus dividend yield?

Regeneus does not currently pay a dividend.

Does Regeneus pay a dividend?

Regeneus does not currently pay a dividend.

When does Regeneus next pay dividends?

Regeneus does not currently pay a dividend.

How do I buy Regeneus shares?

To buy shares in Regeneus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Regeneus?

Shares in Regeneus are currently trading at A$0.11, giving the company a market capitalisation of £17.0m.

Where are Regeneus shares listed? Where are Regeneus shares listed?

Here are the trading details for Regeneus:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: RGS
What kind of share is Regeneus?

Based on an overall assessment of its quality, value and momentum, Regeneus is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Regeneus share price forecast 2021?

We were not able to load any forecast data for Regeneus.

How can I tell whether the Regeneus share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regeneus. Over the past six months, the relative strength of its shares against the market has been -46.05%. At the current price of A$0.11, shares in Regeneus are trading at -6.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Regeneus PE Ratio?

The Regeneus PE ratio based on its reported earnings over the past 12 months is 7. The shares are currently trading at A$0.11.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Regeneus?

Regeneus's management team is headed by:

Graham Vesey - CSO
Barry Sechos - NEC
Duncan Thomson - OTH
Charlotte Morgan - OTH
Sandra McIntosh - DHR
John Bird - CFO
Leo Yao Lee - NED
John Chiplin - NID
Karolis Rosickas - CEO
Who are the major shareholders of Regeneus?

Here are the top five shareholders of Regeneus based on the size of their shareholding:

AGC Inc Corporation
Percentage owned: 7.48% (22.5m shares)
Vesey (Graham) Individual Investor
Percentage owned: 5.29% (15.9m shares)
Lee (Leo Yao) Individual Investor
Percentage owned: 5.29% (15.9m shares)
Kirman 2 Pty. Ltd. Corporation
Percentage owned: 5.25% (15.8m shares)
Eagle Fund SP1 LLP Corporation
Percentage owned: 3.14% (9.44m shares)
Similar to RGS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.